Leading drugmaker Sun Pharma is doubling down on its specialty portfolio, launching new products and ramping up ...
Discover key Royalty Pharma Q3 2025 earnings insights—double-digit growth, new acquisitions, and raised guidance for investors.
Revenue climbed 8.6% to Rs 14,405.2 crore, driven by double-digit growth in India, emerging markets, and rest of world (RoW) ...
This ETF may offer you the best return if you commit to it for the long term. Stock picking is a fantastic way to build ...
Zacks Investment Research on MSN
Pharma ETF (IHE) Hit a 52-Week High
Investors seeking momentum may have iShares U.S. Pharmaceuticals ETF IHE on radar now. The fund recently hit a new 52-week high. Shares of IHE are up approximately 29.6% from their 52-week low of $58.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback